Anti-HBs in immunized children with cuban hepatitis B vaccine and impact of booster dose after five years

Hepatitis B virus infection and associated diseases are a major public health problem. This study was planned to find out the persistence of antibody against hepatitis B surface antigen in Iranian vaccinated children after five years. Anti-HBs titers in a group of healthy good - responder children who were vaccinated with Cuban hepatitis B vaccine in infancy were measured after five years. Children with antibody titers <100mlU/mI were revaccinated and retested after four weeks. Mean anti-HBs titers in 68 children [29 females, 39 males] were 482.1mIU/mL at six months after the third dose of primary vaccination and 153mIU/mL at five years later. Total mean anti-HBs titers in 36 [52.9%] children out of 68 [17 females, 19 males] were 38.3mIU/ml and 4 [5.8%] of 68 children [two of each sexes] had no detectable antibody after five years. Total mean anti-HBs titers in these hypo- responder and non- responder were 774.3mIU/mL and 625.5mIU/mL respectively after booster dose. In a group of children, who were immunized with Cuban hepatitis B vaccine from birth, anti-HBS titers fell at 6.5 years of age and almost half of children became hypo responder or no responder and their anti-HBs titers developed secondary rise after booster vaccination. All children showed immunologic memory to a booster dose

Response of booster dose of cuban recombinant Hepatitis-B vaccine in nonresponder and hyporesponder children

Acute hepatitis B infection can debilitate a patient for weeks and occasionally has a fatal outcome, while chronic infection is a major threat to the individual. To assess response of nonresponder and hyporesponder children to booster dose of Cuban recombinant hepatitis B vaccine. An interventional, descriptive study has been conducted on children who had been immunized with Cuban recombinant Hepatitis B vaccine and their antibody titers were <10mIU/ml [nonresponder] and 10-100mIU/ml [hyporesponder] administered booster dose of the same vaccine in their Deltoid muscles. The response of 141 children with the mean age of 1.9 years to booster dose of vaccine were 94.3% and 100% vaccinees with the first and second booster dose of vaccination respectively. The anti-HBs titer in nonresponders and hyporesponders were 468 +/- 346 and 783 +/- 346mIU/ml respectively with significant differences between two groups [P=0.001]. This study demonstrate moderately increase antibody production in the majority of vaccinees with single supplementary vaccine